Provided by Tiger Trade Technology Pte. Ltd.

ResMed

221.15
+0.05000.02%
Pre-market: 224.002.85+1.29%08:49 EDT
Volume:930.42K
Turnover:206.71M
Market Cap:31.90B
PE:21.20
High:224.14
Open:220.75
Low:219.00
Close:221.10
52wk High:284.87
52wk Low:180.27
Shares:144.25M
Float Shares:143.49M
Volume Ratio:0.99
T/O Rate:0.65%
Dividend:2.40
Dividend Rate:1.09%
EPS(TTM):10.43
EPS(LYR):10.43
ROE:24.27%
ROA:14.00%
PB:4.84
PE(LYR):21.20

Loading ...

Cleveland Medical Devices: Won Favorable Ptab Outcomes in 5 of 6 Resmed Ipr Challenges

THOMSON REUTERS
·
Jul 14

Cleveland Medical Devices: in Four of Five Proceedings, Ptab Determined That Co Had not Established That Challenged Claims were Unpatentable

THOMSON REUTERS
·
Jul 14

Movement Alert|ResMed Falls 5.61% in Regular Trading, Citi Downgrades Rating to Neutral Triggering Sell-Off

Market Focus
·
Jul 13

Movement Alert|ResMed Falls 5.19% in Pre-Market Trading, Citi Downgrades Rating to Neutral

Market Focus
·
Jul 13

RMD or the 4% Rule? One Lets You Live Large and not Run Out of Money.

Dow Jones
·
Jul 13

Resmed Cut to Neutral from Buy by Citigroup

Dow Jones
·
Jul 13

3 US Healthcare Stocks Investors May Revisit As Inflation Pressures Build

Simply Wall St.
·
Jul 13

Citi Downgrades ResMed to Neutral From Buy; Price Target is AU$34

MT Newswires Live
·
Jul 13

ResMed downgraded to Neutral from Buy at Citi

TIPRANKS
·
Jul 13

Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Eli Lilly & Co (LLY)

TIPRANKS
·
Jul 13

RMD or the 4% Rule? One Lets You Live Large and not Run Out of Money.

Dow Jones
·
Jul 11

Resmed is Maintained at Hold by Jefferies

Dow Jones
·
Jul 11

ResMed price target lowered to $225 from $240 at Jefferies

TIPRANKS
·
Jul 10

Jefferies Adjusts Price Target on ResMed to $225 From $240

MT Newswires Live
·
Jul 10

ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan

TIPRANKS
·
Jul 10

Resmed Inc-statement of Changes in Beneficial Ownership

THOMSON REUTERS
·
Jul 10

Statement of Changes in Beneficial Ownership-rmd.n

Reuters
·
Jul 10

ResMed (RMD) After Russell Growth Index Exits Is The Undervalued Narrative Still Intact

Simply Wall St.
·
Jul 10

Nyxoah: Orin Hirchman-controlled Entities Disclose 14.55% Stake, Crossing 10% Threshold

Reuters
·
Jul 10

Resmed CEO Michael Farrell Sells 4,991 Shares for $1.09 Million

Reuters
·
Jul 09